Advances in Therapy

, Volume 26, Issue 6, pp 588–599 | Cite as

Long-acting risperidone: a review of its role in the treatment of bipolar disorder

  • David E. Kemp
  • Fatih Canan
  • Benjamin I. Goldstein
  • Roger S. McIntyre
Review

Abstract

Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid psychiatric and general medical conditions. Indefinite pharmacological treatment is often required, yet the modest effects of available treatments and frequent difficulties with tolerability and adherence present complex challenges to patients. Long-acting injectable medications offer a therapeutic alternative to oral mood stabilizers and may help facilitate long-term treatment adherence. This article will provide a succinct review of the latest data on the use of long-acting injectable risperidone (LAR) during the maintenance-phase treatment of bipolar disorder. The specific role of LAR in comparison to other atypical antipsychotics, and the limitations of available studies will be discussed from the perspectives of efficacy, tolerability, and sequential positioning in treatment guidelines.

Keywords

adherence bipolar disorder long-acting risperidone maintenance phase risperidone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goodwin FK, Jamison KR. Manic-Depressive Illness. 2nd edition. New York, NY: Oxford University Press; 2007.Google Scholar
  2. 2.
    Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352:2515–2523.CrossRefPubMedGoogle Scholar
  3. 3.
    Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ. 1994;72:495–509.PubMedGoogle Scholar
  4. 4.
    Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry. 2007;68:1237–1245.PubMedGoogle Scholar
  5. 5.
    Osby U, Brandt L, Correla N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–850.CrossRefPubMedGoogle Scholar
  6. 6.
    Miller BJ, Paschall CB3rd, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv. 2006;57:1482–1487.CrossRefPubMedGoogle Scholar
  7. 7.
    Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord. 2002;68:167–181.CrossRefPubMedGoogle Scholar
  8. 8.
    Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;6:721–739.CrossRefGoogle Scholar
  9. 9.
    Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160:1263–1271.CrossRefPubMedGoogle Scholar
  10. 10.
    Keck PE,Jr., Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626–637.PubMedGoogle Scholar
  11. 11.
    Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006;8:232–231.CrossRefPubMedGoogle Scholar
  12. 12.
    Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27–38.PubMedGoogle Scholar
  13. 13.
    Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70:91–100.CrossRefPubMedGoogle Scholar
  14. 14.
    Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125–1132.CrossRefPubMedGoogle Scholar
  15. 15.
    Risperdal Consta (risperidone) long-acting injection. Prescribing information. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2008.Google Scholar
  16. 16.
    Hirschfeld RM, Keck PEJr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057–1065.CrossRefPubMedGoogle Scholar
  17. 17.
    Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75–84.CrossRefPubMedGoogle Scholar
  18. 18.
    Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord. 2007;6:551–560.CrossRefGoogle Scholar
  19. 19.
    Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146–1154.CrossRefPubMedGoogle Scholar
  20. 20.
    Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran. Mood stabilizers plus risperidone or placebo in the treatment of acute mania. Br J Psychiatry. 2003;182:141–147.CrossRefPubMedGoogle Scholar
  21. 21.
    Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:229–234.CrossRefPubMedGoogle Scholar
  22. 22.
    Savas HA, Mehmet Y, Murat EO. Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol. 2006;26:530–531.CrossRefPubMedGoogle Scholar
  23. 23.
    Han C, Lee M, Pae C, Ko Y, Patkar AA, Jung I. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1219–1223.CrossRefPubMedGoogle Scholar
  24. 24.
    Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int Clin Psychopharmacol. 2008;23:88–94.CrossRefPubMedGoogle Scholar
  25. 25.
    Vieta E, Nieto E, Autet A, et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry. 2008;23:1–6.Google Scholar
  26. 26.
    Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl. 2007;116:50–56.CrossRefGoogle Scholar
  27. 27.
    Kujawa M, Turner N, Turkoz I, et al. Frequently relapsing bipolar disorder: evidence for an effective treatment. Presented at: 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; Montreux, Switzerland; February 3–7, 2008.Google Scholar
  28. 28.
    Johnson & Johnson Pharmaceutical Research & Development, LLC. 2008. Clinical Trials website. A study of the safety and efficacy of injectable risperidone in the prevention of bipolar mood episodes (NCT00132678). Available at: http://clinicaltrials.gov/ct2/show/NCT00132678. Accessed October 15, 2008.
  29. 29.
    Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;635:384–390.Google Scholar
  30. 30.
    Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther. 2008;30:1358–1374.CrossRefPubMedGoogle Scholar
  31. 31.
    Freyberger HJ, Eerdekens M, Duchesne I, et al. Patient satisfaction with their medication during longacting risperidone injection. Int J Neuropsychopharmacol. 2002;5(suppl. 1):189. Abstract.Google Scholar
  32. 32.
    Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry. 2009;70:196–200.CrossRefPubMedGoogle Scholar
  33. 33.
    Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;667:870–886.CrossRefGoogle Scholar
  34. 34.
    Young A, McElroy S, Olausson B, et al. Quetiapine monotherapy up to 52 weeks in patients with bipolar depression: continuation phase data from EMBOLDEN I & II. Presented at: 21st ENCP Conference; Barcelona, Spain; August 30–September 3, 2008.Google Scholar
  35. 35.
    Vieta E, Suppes T, Eggans I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008;109:251–263.CrossRefPubMedGoogle Scholar
  36. 36.
    Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009;166:476–488.CrossRefPubMedGoogle Scholar
  37. 37.
    Brecher M, Anderssen H, Paulsson P. Quetiapine in the maintenance treatment of bipolar I disorder: combined data from two long-term, phase III studies (NR 3-007). New Research Abstracts. Presented at: Annual Meeting of the American Psychiatric Association 2008; Washington, DC, USA; May 3, 2008.Google Scholar
  38. 38.
    Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225–255.CrossRefPubMedGoogle Scholar
  39. 39.
    Keck PEJr., Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68:1480–1491.PubMedCrossRefGoogle Scholar
  40. 40.
    Kemp DE, Calabrese JR, Van-Tran Q, et al. Components of metabolic syndrome in patients enrolled in a clinical trial of aripiprazole for the maintenance treatment of bipolar disorder. Presented at: American College of Neuropsychopharmacology Annual Meeting; Boca Raton, FL; Dec. 9-13, 2007.Google Scholar
  41. 41.
    Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2008;1653:370–377.CrossRefGoogle Scholar
  42. 42.
    Perlis RH, Ostacher MJ, Patel, JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;1632:217–224.CrossRefGoogle Scholar
  43. 43.
    Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand. 2003;108:4–14.CrossRefPubMedGoogle Scholar
  44. 44.
    Yatham LN. Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am. 2005;28:325–347.CrossRefPubMedGoogle Scholar
  45. 45.
    Nierenberg AA, Ostacher MJ, Calabrese JR. Treatmen-tresistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163:210–216.CrossRefPubMedGoogle Scholar
  46. 46.
    Taylor D. Risperidone long-acting injection practice: more questions than answers? Acta Psychiatr Scand. 2006;114:1–2.CrossRefPubMedGoogle Scholar
  47. 47.
    Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective single-blind pharmacokinetic study. J Clin Psychiatry. 2007;68:1218–1225.PubMedGoogle Scholar
  48. 48.
    Calabrese JR, Kemp DE. Bipolar drug development: are we getting closer to the real world? Am J Psychiatry. 2008;165:1234–1236.CrossRefPubMedGoogle Scholar
  49. 49.
    Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry. 2008;165:1420–1431.CrossRefPubMedGoogle Scholar
  50. 50.
    Clinical Trials website. A study to evaluate the effectiveness and safety of extended-release (ER) paliperidone compared with placebo in delaying the recurrence of symptoms in bipolar I disorder. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00490971?term=paliperidone+ER+bipolar&rank=3. Accessed December 21, 2008.
  51. 51.
    Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63:140–150.CrossRefPubMedGoogle Scholar
  52. 52.
    Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004;18:113–132.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare Communications 2009

Authors and Affiliations

  • David E. Kemp
    • 1
  • Fatih Canan
    • 2
  • Benjamin I. Goldstein
    • 3
  • Roger S. McIntyre
    • 4
  1. 1.Mood & Metabolic Clinic, Case Western Reserve UniversityUniversity Hospitals Case Medical CenterClevelandUSA
  2. 2.Duzce University Medical SchoolDuzceTurkey
  3. 3.Western Psychiatric Institute and ClinicUniversity of Pittsburgh Medical CenterPittsburghUSA
  4. 4.Mood Disorders Psychopharmacology Unit, University Health Network, Associate Professor of Psychiatry and PharmacologyUniversity of TorontoTorontoUSA

Personalised recommendations